Canakci, Mine; Singh, Khushboo; Munkhbat, Oyuntuya; Shanthalingam, Sudarvili; Mitra, Ankita; Gordon, Mallory; Osborne, Barbara A.; Thayumanavan, S. published the artcile< Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine-Loaded Nanogels>, Related Products of 2127-03-9, the main research area is tumor antitumor T cell antibody CD4 mertansine.
CD4+ T lymphocytes play an important role in controlling many malignancies. The modulation of CD4+ T cells through immunomodulatory or cytotoxic drugs could change the course of disease progression for disorders such as autoimmunity, immunodeficiency, and cancer. Here, we demonstrate that anti-CD4 conjugated polymeric nanogels can deliver a small mol. cargo to primary CD4+ T cells and a CD4high T cell lymphoma. The antibody conjugation not only increased the uptake efficiency of the nanogel (NG) by CD4+ T cells but also decreased the non-specific uptake of the NG by CD4- lymphocytes. For T lymphoma cell lines, the mertansine-loaded conjugate displayed a dose-dependent cell growth inhibition at 17 ng/mL antibody concentration On the other hand, antibody-drug conjugate (ADC)-type formulation of the anti-CD4 reached similar levels of cell growth inhibition only at the significantly higher concentration of 1.8μg/mL. NG and antibody conjugates have the advantage of carrying a large payload to a defined target in a more efficient manner as it needs far less antibody to achieve a similar outcome.
Biomacromolecules published new progress about Antibodies and Immunoglobulins Role: BPN (Biosynthetic Preparation), PAC (Pharmacological Activity), THU (Therapeutic Use), BIOL (Biological Study), PREP (Preparation), USES (Uses) (mertansine-polymer conjugates). 2127-03-9 belongs to class pyridine-derivatives, and the molecular formula is C10H8N2S2, Related Products of 2127-03-9.